ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jeff, according to ANIP filings, we are midway through Lalwani's three year plan to complete ANIP's transformation into a sustainable biopharma. Given that ANIP has been reporting negative earnings over the more recent quarters and post approval expenses for Corti exceeded analyst expectations. ANIP's debt and current market jitters combined with institutional opportunistic market manipulation have all contributed to PPS suppression.

Novitium, is a key part of the transformation and we know they have recently received a patent for "Stable oral liquid composition of terazosin" which gives them patent protection beyond February 2041.

The present invention relates to novel stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension.

They have filed a second patent application for Hydrochlorothiazide Compositions. If approved, they will have patent beyond December 2041.

Disclosed herein is a powder for oral suspension and a reconstituted product therein comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema

Getting patent protected products to market will help solidify the sustainability of ANIP's growth.

If Lalwani's is successful in completing his vision. ANIP will gain street credibility as a true sustainable biopharma.

I believe Corti sales will exceed analyst estimates. Hopefully they will be able to articulate sales for expanded indications (ones approved for Corti, but not for Acthar). If this occurs, analyst should start buying into ANIP's vision for Corti as a Blockbuster without going after Acthar's current users. It should alleviate debt concerns and concerns of future dilution.

Then there is the female testosterone wild card.

There a many potential catalyst, which will push PPS north on a long-term sustainable climb firing on all cylinders by the end of 2023.

JMHO.